Rokit Healthcare presents joint Harvard research results at American Society of Nephrology meeting
Predicted impact: Low
Research presentation on AI prediction; same product news already reported; contract termination was a separate prior item.
Rokit Healthcare로킷헬스케어
376900 · KOSDAQ · ₩376900 · 로킷헬스케어
₩16,160▼ ₩750 (4.44%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −53.83%
- Market cap
- ₩283B
- Enterprise value
- ₩245B
- P/E
- —
- P/B
- 41.7×
- Dividend yield
- 0.0%
- ROE
- −187.4%
- Net margin
- −38.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−89.5% from the high
₩15,430Today: ₩15,960 – ₩17,050₩153,800
Returns
- 1W−25.9%
- 1M−42.5%
- 3M−62.2%
- 6M−81.7%
- YTD−75.3%
- 1Y−54.5%
- Volume today
- 165,092
- 0.8× the 20-day average
- Traded today
- ₩2.7B
- Listed shares
- 17,493,263
- EPS (12 months)
- −₩725
- Earnings yield −4.5%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A research presentation at a major medical conference, a generally positive headline. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-45.1% over the last month; the price is below its 20-day average.
- News impactHigh7 news items and filings in two weeks; 1 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Aug 13: sell ₩286M at the close (1.7% of 20-day average trading value)
On its 36 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 1.0% of trading value and pointed the same way 6 of 36 times.
- 2× KODEX KOSDAQ150 Leverage −₩246M
- -1× KODEX KOSDAQ150 Futures Inverse −₩38M
- 2× TIGER KOSDAQ150 Leverage −₩3.2M
- 2× RISE KOSDAQ150 Futures Leverage ₩2.2M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Rokit Healthcare stock overview
Rokit Healthcare (로킷헬스케어, KRX: 376900) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and commercializes an AI-driven, personalized regenerative medicine platform, founded in 2012, that combines AI wound modeling software, a medical 3D bioprinter, single-use sterile regeneration kits, and patient-customized bioinks. Its shares closed at ₩16,160 on Oct 26, 2026, down 4.44% on the day, giving it a market value of ₩283B.
Key facts
- Market cap
- ₩283B
- Sector
- Biotech & Pharma
- Latest price change
- −4.44%
- As of
- Oct 26, 2026
- Main business
- The company develops and commercializes an AI-driven, personalized regenerative medicine platform, founded in 2012, that combines AI wound modeling software, a medical 3D bioprinter, single-use sterile regeneration kits, and patient-customized bioinks.
Quick answers about Rokit Healthcare
- What does Rokit Healthcare do?
- The company develops and commercializes an AI-driven, personalized regenerative medicine platform, founded in 2012, that combines AI wound modeling software, a medical 3D bioprinter, single-use sterile regeneration kits, and patient-customized bioinks. Its main focus areas are skin regeneration (such as diabetic foot ulcers, burns, and skin cancer defect reconstruction), cartilage regeneration for osteoarthritis, and kidney regeneration for chronic kidney disease. Its business model combines initial equipment supply with recurring revenue from kits, bioinks, and software and maintenance services, and it operates in multiple countries through hospital and partner collaborations.
- What is the market cap of Rokit Healthcare?
- The market capitalisation of Rokit Healthcare was ₩283B at the close on Oct 26, 2026.
- Who are the largest shareholders of Rokit Healthcare?
- According to the latest official filings, the largest reported holders are Yu Seok-hwan (25.97%, as of May 21, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.75%, as of Jul 31, 2026); VANGUARD DEVELOPED MARKETS INDEX FUND (1.12%, as of Jun 30, 2026).
- When is the next earnings report from Rokit Healthcare?
- Korean companies rarely announce results dates in advance. Based on when Rokit Healthcare filed the same report in past years, its next preliminary results is expected between Aug 1, 2026 and Nov 6, 2026.
- Does the National Pension Service own Rokit Healthcare?
- Yes. The National Pension Service held 0.19% of Rokit Healthcare shares as of Dec 31, 2025.
Company profile
The company develops and commercializes an AI-driven, personalized regenerative medicine platform, founded in 2012, that combines AI wound modeling software, a medical 3D bioprinter, single-use sterile regeneration kits, and patient-customized bioinks. Its main focus areas are skin regeneration (such as diabetic foot ulcers, burns, and skin cancer defect reconstruction), cartilage regeneration for osteoarthritis, and kidney regeneration for chronic kidney disease. Its business model combines initial equipment supply with recurring revenue from kits, bioinks, and software and maintenance services, and it operates in multiple countries through hospital and partner collaborations.
Written by AI from the company's latest annual report.
- Korean name
- 로킷헬스케어
- Sector
- Biotech & Pharma
- Themes
- AI healthcare
- CEO
- 유석환
- Founded
- Jan 2012
- Listed
- May 2025
- Listed shares
- 17,493,263
- Fiscal year ends
- Month 12
- Website
- rokithealthcare.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent news
Rokit Healthcare Pursues Termination of Contract with US Distributor…Says Unrelated to Product Defects
High impactPredicted impact: High
Termination of US distribution deal for a firm with small revenue; size of contract unknown.
Rokit Healthcare predicts risk for 35 diseases with AI, targets health management market
Predicted impact: Low· Actual: −22.6% vs sector, volume 2.9× normal (5 trading days)
AI disease-prediction product launch; no contract size or financial figures given.
Recent filings
See all- Adjustment of Conversion Price for Convertible Shares (Redeemable Convertible Preferred Shares)Oct 19, 2026
- Amended: Half-year report (Jun 2026)Oct 1, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- Amended: Annual report (Dec 2025)Jul 31, 2026
- [Amended] Decision on Listing of Shares on Overseas Securities Market (Major Management Matter of Subsidiary) (Withdrawn)Jul 28, 2026
Titles in Korean until English translations are added.
Also known as: Rokit Healthcare / 로킷헬스케어 / 376900 / KRX:376900
Source: KRX statistical information